BioCryst Pharmaceuticals Reports Strong Q3 2025 Results

BioCryst Pharmaceuticals ( (BCRX) ) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to its investors.

BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, with its flagship product being ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor.

In its third quarter of 2025, BioCryst Pharmaceuticals reported strong financial results, driven by a significant increase in ORLADEYO net revenue and strategic business decisions. The company also announced the completion of the sale of its European ORLADEYO business and a definitive agreement to acquire Astria Therapeutics.

Key financial highlights include a 37% year-over-year increase in ORLADEYO net revenue to $159.1 million and a 285% increase in operating profit to $29.6 million. The company raised its full-year revenue guidance for ORLADEYO to between $590 million and $600 million and lowered its non-GAAP operating expense guidance. Additionally, the sale of the European business allowed BioCryst to retire all remaining Pharmakon term debt.

Strategically, BioCryst is poised to expand its HAE portfolio with the acquisition of Astria Therapeutics, which includes the promising product candidate navenibart. The company is also advancing its pipeline with trials for BCX17725 and avoralstat, targeting Netherton syndrome and diabetic macular edema, respectively.

Looking ahead, BioCryst remains optimistic about its growth prospects, with expectations of delivering net income and positive cash flows for the full year 2025. The management’s strategic moves and continued focus on innovation are anticipated to drive sustainable growth and profitability in the coming years.